Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis-Reference-Cited by-同舟云学术

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis

Published:2023-05-02 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Signorovitch James¹,Diels Joris²,Van Sanden Suzy²,Schubert Agata³,Hassan Fareen⁴,Thilakarathne Pushpike²,Ozturk Bulent⁴,Barthelmes Norma⁵,Reich Kristian⁶

Affiliation:

1. Analysis Group, Inc, Boston, MA, USA

2. Janssen Pharmaceutica NV, Beerse, Belgium

3. Janssen-Cilag, Warsaw, Poland

4. Janssen-Cilag Ltd, High Wycombe, Buckinghamshire, UK

5. Janssen-Cilag GmbH, Neuss, Germany

6. Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2169574

Reference35 articles.

1. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

2. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

3. The AMCPFormat for Formulary Submissions:Welcome to Version 4.0

4. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

5. Food and Drug Administration. FDA Draft Guidance. Demonstrating substantial evidence of effectiveness for human drug and biological products: guidance for industry; 2019. Available from: https://www.fda.gov/media/133660/download

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy;Journal of Comparative Effectiveness Research;2024-09

2. MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab;The Journal of Allergy and Clinical Immunology: In Practice;2024-08

3. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release;Journal of Managed Care & Specialty Pharmacy;2024-06

4. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-04

5. Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison;Haematologica;2023-11-30